Italia markets open in 4 hours 49 minutes

DSS, Inc. (DSS)

NYSE American - NYSE American Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,3559-0,0116 (-3,16%)
Alla chiusura: 04:00PM EDT
0,3799 +0,02 (+6,74%)
Dopo ore: 07:37PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente0,3675
Aperto0,3675
Denaro0,3630 x 4000
Lettera0,3799 x 3200
Min-Max giorno0,3559 - 0,3800
Intervallo di 52 settimane0,3300 - 1,9400
Volume321.572
Media Volume372.941
Capitalizzazione35,618M
Beta (5 anni mensile)1,63
Rapporto PE (ttm)N/D
EPS (ttm)-0,5190
Prossima data utili22 ago 2022 - 26 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A2,00
  • GlobeNewswire

    DSS’s Impact BioMedical Receives China Patent for its Functional Fragrance Formulation Mosquito Repellant

    China is one of the leading markets globally for insect repellantsHENRIETTA, N.Y., June 07, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced Global BioLife, Inc. (“Global BioLife”), a division of the Company’s wholly

  • GlobeNewswire

    DSS, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

    ROCHESTER, N.Y., May 06, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced that an interview with Chief Operating Officer, Jason Grady, will air on The RedChip Money Report® on Bloomberg U.S., this Saturday May 7th, at 7 p.m. Eastern Time (ET

  • GlobeNewswire

    Impact BioMedical’s Proprietary Equivir Compound to Treat Viral Infection Receives Clean Patentability Report from World Intellectual Property Organization’s ISA Division

    ROCHESTER, N.Y., March 03, 2022 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research and Discovery Group Sciences, (GRDG) announced it had received a positive report regarding the potential international patentability of its proprietary compound Equivir to treat viral infections which has shown potential to limit the occurrence of, and reduce, the risk or severity of viral outbreaks. W